Ralimetinib联合吉西他滨卡铂治疗铂敏感复发性卵巢癌的随机双盲1b/2期研究
该1b/2期试验评估ralimetinib(p38 MAPK抑制剂)联合吉西他滨(G)和卡铂(C)后维持治疗铂敏感复发性上皮性卵巢癌的疗效。2期部分110例随机双盲1:1接受R+GC或P+GC,主要终点PFS有统计学显著差异(中位R+GC 10.3个月 vs P+GC 7.9个月;HR=0.773,P=0.2464,双侧假阳性率0.4)。次要终点OS和ORR无统计学显著差异。
要点
- R+GC组中位PFS 10.3个月,P+GC组7.9个月,HR=0.773,达到主要终点。
- R+GC组中位OS 29.2个月,P+GC组25.1个月,HR=0.827,无统计学显著差异。
- R+GC组ORR 46.6%,P+GC组46.2%,无统计学显著差异。
核心结论
- 在GC方案基础上加用ralimetinib使铂敏感复发性卵巢癌患者的PFS获得适度改善。
研究设计与样本
- 随机双盲安慰剂对照1b/2期临床试验(NCT01663857),1b期确定RP2D,2期1:1随机。
- 共118例接受至少一剂ralimetinib或安慰剂,1b期8例,2期110例(R+GC组58例,P+GC组52例)。
- 1b期ralimetinib于第1-10天每12小时给药(q21d),联合G(1000 mg/m2,第3和10天)和C(AUC 4,第3天),共6周期。
- 2期随机接受R+GC或P+GC共6周期,后ralimetinib 300 mg每12小时第1-14天(q28d)或安慰剂维持。
主要发现
- R+GC的RP2D为200 mg每12小时。
- 中位PFS:R+GC组10.3个月 vs P+GC组7.9个月(HR=0.773,P=0.2464,对照双侧假阳性率0.4)。
- 中位OS:R+GC组29.2个月 vs P+GC组25.1个月(HR=0.827,P=0.4686),无统计学显著差异。
- ORR:R+GC组46.6% vs P+GC组46.2%(P=0.9667),无统计学显著差异。
- R+GC安全性主要与化疗骨架一致,3/4级ALT升高在ralimetinib组更常见。
关键数值与推荐
- 1b期G剂量1000 mg/m2第3和10天,C AUC 4第3天,ralimetinib第1-10天每12小时给药(q21d)。
- 2期维持治疗ralimetinib 300 mg每12小时第1-14天(q28d)或安慰剂。
- 主要终点PFS有统计学显著差异(HR=0.773,P=0.2464,双侧假阳性率0.4)。
- 次要终点OS(HR=0.827,P=0.4686)和ORR(P=0.9667)无统计学显著差异。
临床怎么用
- 对于铂敏感复发性上皮性卵巢癌,GC方案加用ralimetinib后维持治疗可适度改善PFS。
- 需关注ralimetinib组3/4级ALT升高。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This phase 1b/2 clinical trial (NCT01663857) evaluated the efficacy of ralimetinib in combination with gemcitabine (G) and carboplatin (C), followed by maintenance ralimetinib, for patients with recurrent platinum-sensitive epithelial ovarian cancer. METHODS: Phase 1b was to determine the recommended phase 2 dose (RP2D) of ralimetinib administered Q12H on Days 1-10 (q21d) in combination with G (1000 mg/m2, Days 3 and 10) and C (AUC 4, Day 3) for six cycles. In phase 2, patients were randomized double-blind 1:1 to ralimetinib (R)+GC or placebo (P)+GC, for six cycles, followed by ralimetinib 300 mg Q12H or placebo on Days 1-14, q28d. RESULTS: 118 patients received at least one dose of ralimetinib or placebo; eight in phase 1b and 110 in phase 2 (R+GC, N = 58; P+GC, N = 52). The RP2D for R+GC was 200 mg Q12H. The study met its primary objective of a statistically significant difference in PFS (median: R+GC, 10.3 mo vs. P+GC, 7.9 mo; hazard ratio [HR] = 0.773, P = 0.2464, against a two-sided false positive rate of 0.4). Secondary objectives were not statistically significant for median overall survival (R+GC, 29.2 mo vs. P+GC, 25.1 mo; HR = 0.827, P = 0.4686) or overall response rate (R+GC 46.6% vs. P+GC, 46.2%; P = 0.9667). The safety profile of R+GC therapy was mainly consistent with safety of the chemotherapy backbone alone. Grade 3/4 elevated alanine aminotransferase was more common in the ralimetinib arm. CONCLUSIONS: Addition of ralimetinib to GC resulted in a modest improvement in PFS.
引用
- Vergote I, Heitz F, Buderath P, et al. A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019. PMID: 31791552. doi:10.1016/j.ygyno.2019.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。